Abstract: A formulation, method, and apparatus for treating neoplasms such as cancer by administering a pharmaceutically effective amount of highly toxic composition by inhalation, wherein the composition is a non-encapsulated antineoplastic drug.

Abstract: The present invention relates to a method for preparing an oral formulation containing acid-sensitive drugs, including at least the following step: spreading a solution or a suspension containing at least stabilizers, solvents and acid-sensitive drugs or its pharmaceutically acceptable salts onto a core made from one or more excipients, and then drying the core to make an active ingredient layer over the core. Also disclosed is the oral formulation made by this method.

Abstract: A pharmaceutical MR (modified release) multiparticulate dosage form such as a capsule (once-a-day MR Capsule) of Methylphenidate indicated for the treatment of children with attention deficit hyperactivity disorder (ADHD), capable of delivering a portion of the dose for rapid onset of action and the remainder of the dose in a controlled manner for about 12 hours, is composed of a multitude of multicoated particles made of two populations of drug layered beads, IR (immediate release) and ER (extended release) Beads. The IR beads preferably are made by layering an aqueous solution comprising a drug and a binder on to non-pareil sugar spheres and then applying a seal coat to the drug coated cores. The ER Beads are made by applying an extended release coating of a water insoluble dissolution rate controlling polymer such as ethylcellulose to IR Beads.

Abstract: A composition is disclosed for freshening sinus cavities, including a carrier of the ingredients and a masking agent for concealing or eliminating odors that emanate from the sinus cavities. The disclosure is also related to a composition for cleansing and freshening nostrils and sinus cavities that includes a saline solution as a moisturizing base component, a flavoring agent, a preservative, an antiseptic and/or anti-microbial agent, a counter-irritant, and an alcohol. The disclosure is also related to the use of such composition to provide many unexpected benefits of clean and healthy nasal and sinus passages.

Abstract: A process for making up or caring for keratin fibers. A cosmetic composition comprising fibers and at least one film-forming polymer in the form of particles in aqueous dispersion is applied to the keratin fibers.

Abstract: To provide a transmucous absorption enhancer comprising a medium-chain fatty acid salts or a bile acid salt and a glycyrrhizic acid salts capable of sustaining the effect of the absorption enhancer and allowing an agent (especially a physiologically active peptide) to be absorbed via a mucosa (especially a large intestine mucosa).

Abstract: Novel administration form for acid-labile active compounds are described. The novel administration forms have no enteric layers and are suitable for oral administration.

Abstract: Cosmetic skin care compositions containing alpha interferon are provided. The compositions improve the appearance of aged or damaged skin.

Abstract: The present invention relates to starch granules made completely on the basis of starch and to a process for producing these granules. The process comprises the use of a slurry of pregelatinised starch and starch granules to coat in multiple layers starch seeds. The granules so obtained are useful for immobilisation of desired products, which include such divers products as enzymes, pharmaceuticals, colorants, flavours.

Abstract: The present invention relates to a new solid controlled-release pharmaceutical composition obtained by thermoforming, in the hot state, a mixture based on polymers belonging to the polymethacrylate family and medicinal active ingredient(s).

Abstract: The present invention is directed to an active agent dosage that is useful for the prolonged delivery of an active agent formulation to fluid environment of use. The active agent dosage form is a matrix that has an insoluble material circumscribing a portion of the surface of the matrix. The invention is also directed to a method of making the active agent dosage form.

Abstract: Barrier creams are described which are useful in protecting a user from burns during exposure to heat. The creams comprise a base cream with at least one of a melt additive and a reflective additive, or ideally both a melt additive and a reflective additive. The cream preferably is waterproof and has an acceptable longevity of application.

Abstract: A pharmaceutical composition comprising a cyclosporin solid-state microemulsion is disclosed. In a preferred embodiment, the composition comprises a cyclosporin microemulsion dispersed in an enteric carrier. The composition does not dissolve in external phases such as artificial gastric fluid, but dissolves rapidly in artificial intestinal fluid, whereby it releases the cyclosporin microemulsion, providing rapid delivery of cyclosporin. The composition effectively maintains a therapeutic blood concentration of cyclosporin with once a day dosing, providing for convenience of administration and avoiding adverse effects induced by increasing peak blood cyclosporin concentrations associated with conventional cyclosporin formulations.

Abstract: The present invention relates to an oral pharmaceutical preparation which contains an acid or base labile pharmaceutical ingredient which is embedded in an oily matrix which is controlled at neutral pH. The oily matrix-embedded pharmaceutical ingredient is encapsulated and then being coated by an enteric coating. The enteric coating enables the pharmaceutical ingredient to reach the small intestine for absorption. The oily matrix has the advantages of avoiding acidic or basic conditions. It can also isolate moisture and oxygen so as to allow for greater absorption and bioavailability of the pharmaceutical ingredient in vivo.

Abstract: A controlled release preparation containing at least one kind of a pharmaceutically active ingredient, a male piece and a female piece, the pieces fitting together to enclose the active substance therein, wherein the male piece is made from a material that gels in the intestinal juice, is disclosed. In a preferable mode, the male piece contains an ethyl acrylate-methyl methacrylate-trimethylammonioethyl methacrylate chloride copolymer and a methacrylic acid-ethyl acrylate copolymer. In a preferable mode, the female piece is made from a water insoluble polymer. In a preferable mode, the dosage form is a tablet or a capsule.

Abstract: Bacterial infections may be treated using a high dosage regimen of amoxycillin. Preferably, the dosage is provided by a bilayer tablet.

Abstract: A buccal dosage unit is provided for administering a combination of steroidal active agents to a female individual. The novel buccal drug delivery systems may be used in female hormone replacement therapy, in female contraception, to treat female sexual dysfunction, and to treat or prevent a variety of conditions and disorders which are responsive to the active agents discussed herein. The buccal dosage unit comprises a progestin, an estrogen and optionally an androgenic agent, as well as a polymeric carrier that bioerodes and provides for delivery of the active agents throughout a predetermined drug delivery period.

Abstract: The invention concerns fatty acids uninterrupted by a methylene group as anti-inflammatory agents in superficial tissues of mammals, more particularly a pharmaceutical or cosmetic topical composition comprising, as an active ingredient, at least one fatty acid uninterrupted by a methylene group corresponding to formula (I), an salt or ester thereof, wherein R1 is a C1-C5 alkyl group and R2 is a C2-C6 alkyl group. Preferably, the fatty acid uninterrupted by a methylene group is 20:3(5,11,14). The fatty acid uninterrupted by a methylene group is also used for preparing a composition for modulating the metabolism of lipids in the superficial tissue of mammals.

Abstract: A dietary supplement system having a daytime component and a nighttime component is provided, wherein the daytime component comprises at least one thermogenic substance and the nighttime component comprises at least one adrenal support substance.

Abstract: A pre-vaccination or pre-procedural topical anesthetic patch which functions not unlike a nicotine patch and which is essentially a round Band-Aid® (trademark) containing a topical anesthetic. The Band-Aid® anesthetic carrying device may be of any shape or size. It is applied to a persons skin at a site where a needle is to be inserted such that the site will have a topical anesthetic applied. When the Band-Aid® is removed from the site prior to a needle being inserted a visible delineation of a target area is visible on the skin. That is, that side of the Band-Aid® which contacts the skin will contain a dye, of any color, although preferably red, in the form of a circle or any other geometric shape, smaller than the diameter or size of the Band-Aid®, whereby when the Band-Aid® is removed the dye will leave a mark at the site which is the “target” area.